Anheuser-Busch InBev SA/NV BUD, aka AB InBev, reported first-quarter 2025 results. The company’s earnings per share (EPS) beat the Zacks Consensus Estimate and improved year over year. However, the top line declined and missed the Zacks Consensus Estimate. Bottom-line growth reflected positive business momentum, owing to the strength of its diversified footprint and consumer demand for its megabrands. AB InBev reported an underlying EPS (normalized EPS, excluding mark-to-market gains and losses related to the hedging of share-based payment programs and the impacts of hyperinflation) of 81 cents, up 7.1% year over year. The rise was driven by 10.3% EBIT growth and the continued optimization of net finance costs. The bottom line beat the Zacks Consensus Estimate of 77 cents. On a constant-currency basis, underlying EPS improved 20.2%. Revenues of $13.63 billion missed the Zacks Consensus Estimate of $13.85 billion and declined 6.3% year over year. The company registered organic revenue growth of 1.5%, led by revenue growth in 50% of its markets. Growth across markets was driven by a focus on ongoing premiumization and disciplined revenue management, contributing to higher revenue per hectoliter (hl). Shares of this Zacks Rank #3 (Hold) company have rallied 33.1% in the past three months compared with the industry’s 19.3% growth.Zacks Investment Research Image Source: Zacks Investment Research BUD’s Q1 Details Revenue per hl improved 3.7% year over year in the quarter, backed by revenue-management initiatives. The total organic volume fell 2.2%, including a decline of 2.5% in the own-beer volume and 0.2% in the non-beer volume. Revenues reflected the strong performances of its premium and super premium beer brands. The company’s above-core beer portfolio registered 1.8% year-over-year growth. Within the above-core brands, Corona led the performance with an 11.2% revenue increase outside of Mexico, including double-digit volume growth in more than 30 markets. Megabrands revenues increased 4.4%, again led by strong performance in the Corona brand. AB InBev has been keen on making investments in its portfolio over the years, and rapidly growing its digital platform, including BEES and Zé Delivery. Its digital transformation initiatives have been on track, with B2B digital platforms contributing about 72% to its revenues in first-quarter 2025. Its omnichannel, direct-to-consumer ecosystem of digital and physical products generated $275 million in revenues in first-quarter 2025. BUD has been focused on expanding its Beyond Beer portfolio, which has also been aiding the top line. Notably, the Beyond Beer portfolio recorded a 16.6% revenue rise, driven by double-digit growth in key brands such as Cutwater and Nütrl in the United States, and Beats in Brazil. Story Continues Anheuser-Busch InBev SA/NV Price, Consensus and EPS SurpriseAnheuser-Busch InBev SA/NV Price, Consensus and EPS Surprise Anheuser-Busch InBev SA/NV price-consensus-eps-surprise-chart | Anheuser-Busch InBev SA/NV Quote The cost of sales dipped 9.2% on a reported basis to $6.04 billion and was up 3.1% on an organic basis. SG&A expenses increased 5.6% year over year on a reported basis and 1.3% on an organic basis to $4.2 billion. Our model had predicted the cost of sales to decline 6.4%, with a 160-basis-point (bps) decline in the cost-of-sales rate to 44.1%. We estimated a 30-bps year-over-year increase in the SG&A expense rate to 30.8%. In dollar terms, SG&A expenses were expected to decline 1.8% year over year. The company’s normalized earnings before interest, taxes, depreciation and amortization (EBITDA) were $4.9 billion, which fell 2.6% year over year on a reported basis and improved 7.9% on an organic basis. The normalized EBITDA margin expanded 130 bps year over year on a reported basis and 218 bps organically to 35.6%. The organic EBITDA margin benefited from cost efficiencies and disciplined overhead management. We anticipated normalized EBITDA to rise 2.2% year over year to $5.1 billion. Meanwhile, the normalized EBITDA margin was expected to expand 180 bps to 36.1%. BUD’s 2025 Outlook For 2025, AB InBev expects year-over-year EBITDA growth of 4-8%, in line with its medium-term outlook. The company expects net pension interest expenses and accretion expenses of $190-$220 million per quarter in 2025, based on currency and interest rate fluctuations. It anticipates an average gross debt coupon of 4% in 2025. Management expects a normalized effective tax rate of 26-28% for 2024. Net capital expenditure is projected to be $3.5-$4 billion. Key Picks Carlsberg CABGY, a brewing company with a beer portfolio of more than 500 brands, currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here. The Zacks Consensus Estimate for Carlsberg’s current financial-year sales and EPS indicates growth of 31.2% and 9.4%, respectively, from the prior-year reported levels. The Coca-Cola Company KO is a beverage behemoth with a market share of more than 40% in the non-alcoholic beverage industry. It currently has a Zacks Rank of 2 (Buy). The Zacks Consensus Estimate for Coca-Cola’s current financial-year sales and EPS indicates growth of 2.3% and 2.8%, respectively, from the prior-year reported levels. KO has a trailing four-quarter earnings surprise of 4.9%, on average. Keurig Dr Pepper Inc. KDP is a prominent integrated brand owner, manufacturer, and distributor of beverages across the United States, Canada, Mexico and the Caribbean. The company currently carries a Zacks Rank #2. The Zacks Consensus Estimate for Keurig’s current financial-year sales and EPS indicates growth of 5.6% and 6.3%, respectively, from the year-ago reported figures. KDP delivered a trailing four-quarter earnings surprise of 3.1%, on average. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report CocaCola Company (The) (KO):Free Stock Analysis Report Anheuser-Busch InBev SA/NV (BUD):Free Stock Analysis Report Carlsberg AS (CABGY):Free Stock Analysis Report Keurig Dr Pepper, Inc (KDP):Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research View Comments
AB InBev Q1 Earnings Beat on Brand Momentum, Revenues Fall Short
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research.
Start Your Free Trial Now!Not sure where to invest today?
Kalkine’s latest research highlights three companies identified through in-depth analysis and market insights.
Explore these research reports to learn about companies currently being tracked by our analysts and make more informed investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...